Abstract Library

#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET

Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: CROS J

Authors: Bucau M, Cros J, Raffenne J, Rebours V, Palazzo M,

Keywords: PNET, everolimus, predictive biomarkers,

#1196 CBEZ235Z2401: Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)

Introduction: EVE is an mTOR inhibitor (mTORi) approved for the treatment of advanced pNETs. BEZ235, a dual mTOR/PI3K inhibitor, may provide greater PI3K pathway inhibition and enhanced antitumor effects.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Libutti S, Garcia-Carbonero R, Wolin E, Custodio A, Yao J,

Keywords: pNET, BEZ235, everolimus,

#1166 mTOR Pathway Inhibition Sensitizes Insulinoma Cells to Streptozotocin Induced Apoptosis

Introduction: Pancreatic neuroendocrine tumors (pNETs) are generally chemoresistants probably due to low proliferation rate and defects in apoptotic pathway. Targeted therapies are new encouraging options for pNETs however; clinical trials show limited objective response. Combination of chemotherapy and targeted therapy could be a new solution in therapeutic care. Streptozotocin (STZ) is the 1st line of therapy for unresectable pNETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Vercherat C

Authors: Vercherat C, Walter T, Massoma-Peh P, Bollard J, Lacheretz-Bernigaud A,

Keywords: neuroendocrine, therapy, Streptozotocin, mTOR pathway, combination, pre-clinical study,

#1036 Abrogation of Autophagy by Chloroquine in Neuroendocrine Tumor Cells Treated with mTOR Inhibitors Induces Apoptosis, While Reduction of Cell Proliferation is Due to a Chloroquine, Autophagy Unrelated, Lysosomal Effect

Introduction: The therapy options for patients with advanced NETs are limited. The mTOR inhibitors (mTORi), Torin1 and NVP-BEZ235, are known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to prolong survival, evading the anti-cancer effect. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to inhibit autophagy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Avniel- Polak S

Authors: Avniel-Polak S, Leibowitz G, Glaser B, Gross D, Grozinsky-Glasberg S,

Keywords: NETs, autophagy, mTORi ,

#921 Combined Therapy with RAD001 e BEZ235 Overcomes Resistance of PET Cells to mTOR Inhibition

Introduction: Since the PI3K/Akt/mTOR proliferation axis is often deregulated in PETs, the mTORC1 complex inhibitor Everolimus (RAD001) represents an effective treatment for PETs. However, RAD001 leads to a re-activation of PI3K activity and phosphorylation of Akt, which may promote resistance to the treatment. Thus, direct inhibition of PI3K may represent a novel potential target for PETs.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Passacantilli I, Capurso G, Archibugi L, Calabretta S, Delle Fave G,

Keywords: mTOR, PI3K, resistance,